NewAmsterdam Pharma Company N.V. (NAMSW)

Compare

7.32

+0.18

+(2.52%)

At close: April 2 at 4:00:00 PM EDT

Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?

AstraZeneca said Monday its experimental pill lowered "bad" LDL cholesterol by 51%. But AstraZeneca stock fell in line with pharma stocks.

Investor's Business Daily 2 days ago

NAMS
-0.92%
NAMSW
+2.52%
AZN
NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference

NAARDEN, the Netherlands and MIAMI, March 31, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Ian Somaiya, Chief Financial Officer of New

GlobeNewswire 2 days ago

NAMS
-0.92%
NAMSW
+2.52%
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Yearly Results: Here's What Analysts Are Forecasting For This Year

Shareholders of NewAmsterdam Pharma Company N.V. ( NASDAQ:NAMS ) will be pleased this week, given that the stock price...

Simply Wall St. last month

NAMS
-0.92%
NAMSW
+2.52%
NewAmsterdam Pharma Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

NewAmsterdam Pharma ( NASDAQ:NAMS ) Full Year 2024 Results Key Financial Results Revenue: US$45.6m (up 223% from FY...

Simply Wall St. last month

NAMS
-0.92%
NAMSW
+2.52%
NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update

-- EMA submission expected in 2H25 by partner Menarini -- -- Additional data from BROADWAY, BROOKLYN, and TANDEM to be presented throughout 2025 -- -- Phase 3 PREVAIL CVOT remains on track -- -- $834.2 million in cash, cash equivalents and marketable securities at December 31, 2024 -- NAARDEN, the Netherlands and MIAMI, Feb. 26, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing

GlobeNewswire last month

NAMS
-0.92%
NAMSW
+2.52%
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March

NAARDEN, The Netherlands and MIAMI, Feb. 25, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the f

GlobeNewswire last month

NAMS
-0.92%
NAMSW
+2.52%
Both private equity firms who control a good portion of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) along with institutions must be dismayed after last week's 8.1% decrease

Key Insights NewAmsterdam Pharma's significant private equity firms ownership suggests that the key decisions are...

Simply Wall St. last month

NAMS
-0.92%
NAMSW
+2.52%
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NAARDEN, the Netherlands and MIAMI, Feb. 07, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s

GlobeNewswire last month

NAMS
-0.92%
NAMSW
+2.52%
NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference

NAARDEN, The Netherlands and MIAMI, Jan. 29, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Ian Somaiya, Chief Financial Officer of NewA

GlobeNewswire 2 months ago

NAMS
-0.92%
NAMSW
+2.52%
NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities

-- Additional data from BROADWAY, BROOKLYN, and TANDEM to be presented throughout 2025; expected to support global regulatory filings for obicetrapib, including EMA submission in 2H25 by our partner Menarini – -- Data from Phase 2 VINCENT trial expected by 2H25, which explores effect of obicetrapib alone and in combination with a PCSK9i on Lp(a) – -- Focus on commercial readiness with manufacturing capacity establishment and inventory build-out -- -- Year end, unaudited, cash balance of $835 mil

GlobeNewswire 2 months ago

NAMS
-0.92%
NAMSW
+2.52%
NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

NAARDEN, The Netherlands and MIAMI, Dec. 13, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the closing of the previously announced underwritte

GlobeNewswire 3 months ago

NAMS
-0.92%
NAMSW
+2.52%
NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

NAARDEN, the Netherlands and MIAMI, Dec. 11, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the pricing of the previously announced underwritte

GlobeNewswire 3 months ago

NAMS
-0.92%
NAMSW
+2.52%
NewAmsterdam Pharma Stock Hits 90-Plus RS Rating

NewAmsterdam Pharma shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

Investor's Business Daily 3 months ago

ADMA

CORT

CPRX
NewAmsterdam Pharma Soars 41% On A Surprise Benefit From Cholesterol Drug

NewAmsterdam Pharma said Tuesday its cholesterol drug lowered the risk of major cardiovascular events and the biotech stock catapulted.

Investor's Business Daily 3 months ago

NAMS
-0.92%
NAMSW
+2.52%
NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

NAARDEN, The Netherlands and MIAMI, Dec. 10, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the commencement of an underwritten public offering

GlobeNewswire 3 months ago

NAMS
-0.92%
NAMSW
+2.52%
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia

-- Achieved primary endpoint of LS mean reduction vs placebo in LDL-C on top of maximally tolerated lipid modifying therapies at day 84 with statistically significant reduction (p<0.0001) -- -- 21% observed reduction in major adverse cardiovascular events favoring obicetrapib at one year – -- Observed to be well-tolerated with safety results comparable to placebo -- -- NewAmsterdam to host conference call at 8:00 a.m. ET today -- NAARDEN, The Netherlands and MIAMI, Dec. 10, 2024 (GLOBE NEWSWIRE)

GlobeNewswire 3 months ago

NAMS
-0.92%
NAMSW
+2.52%
NewAmsterdam Pharma Reports Promising Phase 3 Trial Results

The latest update is out from NewAmsterdam Pharma Company ( (NAMS) ). NewAmsterdam Pharma has announced promising results from its Phase 3 TANDEM clinical trial, showcasing the effectiveness of a fixed-dose combination of obicetrapib and ezetimibe in significantly reducing LDL-C levels in patients with cardiovascular disease or high-risk factors. The trial met its primary endpoints, demonstrating a 50% reduction in LDL-C compared to placebo, and showed that over 70% of patients achieved LDL-C le

TipRanks 4 months ago

NAMS
-0.92%
NAMSW
+2.52%
NewAmsterdam Dives — And Sacrifices A Cup Base — Despite A Winning Cholesterol Study

NewAmsterdam Pharma crashed Wednesday after the company said its experimental cholesterol treatment lowered "bad" LDL by roughly 50%

Investor's Business Daily 4 months ago

NAMS
-0.92%
NAMSW
+2.52%
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH

-- Achieved all co-primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies versus each of placebo, ezetimibe 10 mg, and obicetrapib 10 mg monotherapy at day 84 with statistical significance (p<0.001) -- -- Obicetrapib and ezetimibe fixed-dose combination observed to lower LDL-C by approximately 50% at day 84, compared to placebo, with over 70% of patients achieving LDL-C levels below 55 mg/dL -- -- Data supports global regulatory filings of the obi

GlobeNewswire 4 months ago

NAMS
-0.92%
NAMSW
+2.52%
NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024

– Met primary endpoint with LDL-C mean reduction versus placebo of 36.3% at day 84 and 41.5% at day 365 – – Lp(a) mean reduction versus placebo of 45.9% at day 84 and 54.3% at day 365 – – Total LDL-P mean reduction versus placebo of 52.5% at day 180, with small LDL-P reduction of 102.4% – – Safety results comparable to placebo – NAARDEN, the Netherlands and MIAMI, Nov. 18, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, c

GlobeNewswire 4 months ago

NAMS
-0.92%
NAMSW
+2.52%

Performance Overview

Return	NAMSW	S&P 500 (^GSPC)
YTD	-48.63%	-3.58%
1-Year	-28.59%	+8.94%
3-Year	+3,110.53%	+24.75%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

NewAmsterdam Pharma Company N.V. (NAMSW)

Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?

NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Yearly Results: Here's What Analysts Are Forecasting For This Year

NewAmsterdam Pharma Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March

Both private equity firms who control a good portion of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) along with institutions must be dismayed after last week's 8.1% decrease

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference

NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities

NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

NewAmsterdam Pharma Stock Hits 90-Plus RS Rating

NewAmsterdam Pharma Soars 41% On A Surprise Benefit From Cholesterol Drug

NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia

NewAmsterdam Pharma Reports Promising Phase 3 Trial Results

NewAmsterdam Dives — And Sacrifices A Cup Base — Despite A Winning Cholesterol Study

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH

NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024

Performance Overview